Cite
HARVARD Citation
Candoni, A. et al. (n.d.). Flai (fludarabine, cytarabine, idarubicin) plus low‐dose Gemtuzumab Ozogamicin as induction therapy in CD33‐positive AML: Final results and long term outcome of a phase II multicenter clinical trial. American journal of hematology. 93 (5), pp. 655-663. [Online].